BLTE vs. ROIV, SRPT, RVMD, BBIO, LNTH, TGTX, LEGN, AXSM, TLX, and BPMC
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.
Belite Bio vs.
Roivant Sciences (NASDAQ:ROIV) and Belite Bio (NASDAQ:BLTE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, Belite Bio had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 19 mentions for Belite Bio and 17 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.66 beat Belite Bio's score of 0.16 indicating that Roivant Sciences is being referred to more favorably in the media.
Roivant Sciences has higher revenue and earnings than Belite Bio. Roivant Sciences is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.
Roivant Sciences currently has a consensus price target of $17.10, indicating a potential upside of 60.26%. Belite Bio has a consensus price target of $96.33, indicating a potential upside of 49.35%. Given Roivant Sciences' higher possible upside, research analysts clearly believe Roivant Sciences is more favorable than Belite Bio.
Belite Bio has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Belite Bio's return on equity.
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Roivant Sciences has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.54, meaning that its share price is 254% less volatile than the S&P 500.
Roivant Sciences received 21 more outperform votes than Belite Bio when rated by MarketBeat users. However, 97.06% of users gave Belite Bio an outperform vote while only 78.26% of users gave Roivant Sciences an outperform vote.
Summary
Roivant Sciences beats Belite Bio on 11 of the 16 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
This page (NASDAQ:BLTE) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy BLTE Stock Free BLTE Stock Alerts